{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:56:17Z","timestamp":1790823377947,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":548,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.exphem.2025.104746","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T17:48:48Z","timestamp":1739382528000},"page":"104746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Preconditioning intervention prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-4459","authenticated-orcid":false,"given":"Takayoshi","family":"Tachibana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9900-4421","authenticated-orcid":false,"given":"Akihiko","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuki","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yotaro","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuku","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumichi","family":"Fujimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3808-4006","authenticated-orcid":false,"given":"Etsuko","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-230X","authenticated-orcid":false,"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8967-4954","authenticated-orcid":false,"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2025.104746_bib0001","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/s41375-019-0494-9","article-title":"Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis","volume":"33","author":"Tachibana","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104746_bib0002","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3324\/haematol.2022.280798","article-title":"New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia","volume":"108","author":"Mohty","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2025.104746_bib0003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-018-0203-8","article-title":"Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia","volume":"54","author":"Craddock","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104746_bib0004","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3390\/ijms20010228","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: prevention, detection, and treatment","volume":"20","author":"Rautenberg","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2025.104746_bib0005","first-page":"1","article-title":"Post-transplant maintenance therapy: emerging concepts and future perspectives","volume":"13","author":"Matsuoka","year":"2024","journal-title":"Jpn J Transplant Cell Ther"},{"key":"10.1016\/j.exphem.2025.104746_bib0006","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41409-018-0286-2","volume":"54","author":"Lee","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104746_bib0007","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12185-023-03596-w","article-title":"Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS","volume":"118","author":"Najima","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.exphem.2025.104746_bib0008","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12185-022-03416-7","article-title":"Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment","volume":"116","author":"Kreidieh","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.exphem.2025.104746_bib0009","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2025.104746_bib0010","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s00277-020-04131-1","article-title":"The FLAMSA concept-past and future","volume":"99","author":"Kolb","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2025.104746_bib0011","doi-asserted-by":"crossref","first-page":"70.e1","DOI":"10.1016\/j.bbmt.2020.09.025","article-title":"Clinical benefits of preconditioning intervention in patients with relapsed or refractory acute myelogenous leukemia who underwent allogeneic hematopoietic cell transplantation: a kanto study of group for cell therapy multicenter analysis","volume":"27","author":"Tachibana","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.exphem.2025.104746_bib0012","first-page":"1279","article-title":"Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan","volume":"46","author":"Miyawaki","year":"2005","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.exphem.2025.104746_bib0013","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12185-015-1882-1","article-title":"Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood","volume":"103","author":"Kitamura","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.exphem.2025.104746_bib0014","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104746_bib0015","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104746_bib0016","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104746_bib0017","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104746_bib0018","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104746_bib0019","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/ejh.13664","article-title":"Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS","volume":"107","author":"Rautenberg","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2025.104746_bib0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/bmt.2014.209","article-title":"Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation","volume":"50","author":"Israyelyan","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104746_bib0021","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41408-022-00678-6","article-title":"Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia","volume":"12","author":"Konuma","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2025.104746_bib0022","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41409-023-01987-5","article-title":"Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse","volume":"58","author":"Kent","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104746_bib0023","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1111\/cas.15048","article-title":"Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"112","author":"Wei","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.exphem.2025.104746_bib0024","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/s41409-023-01961-1","article-title":"Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"58","author":"Abou Dalle","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104746_bib0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41375-023-02119-0","article-title":"Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission","volume":"38","author":"Yanada","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104746_bib0026","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bjh.19552","article-title":"Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia","volume":"205","author":"Ronnacker","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2025.104746_bib0027","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.bbmt.2016.06.017","article-title":"A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies","volume":"22","author":"Yamamoto","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104746_bib0028","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.bbmt.2013.12.555","article-title":"Single-unit cord blood transplantation after granulocyte colony-stimulating factor-combined myeloablative conditioning for myeloid malignancies not in remission","volume":"20","author":"Konuma","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104746_bib0029","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"Lancet Haematol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X25000372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X25000372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:20:39Z","timestamp":1790821239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X25000372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":29,"alternative-id":["S0301472X25000372"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2025.104746","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preconditioning intervention prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2025.104746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Experimental Hematology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104746"}}